摘要
目的探讨重组人脑钠肽注射液对急性心力衰竭患者的临床疗效,并分析远期临床疗效。方法 94例患者随机分为对照组和观察组,对照组给予常规治疗,观察组在对照组的基础上给予重组人脑钠肽注射液治疗,比较两组患者近远期疗效。结果观察组较对照组6 min步行距离更长,LVEF增加,24 h尿量更多,呼吸改善明显,BNP下降更明显(P<0.05);观察组总有效率高于对照组(72.3%vs 49.0%,P<0.05);观察组再住院及死亡患者数较对照组减少(P<0.05)。结论重组人脑钠肽注射液对急性心力衰竭患者近期疗效显著,且可降低再住院率和死亡率。
Objective To explore the effect of long-term prognosis of recombinant human brain natriuretic peptide on heart failure. Methods 94 cases were divided into two group. The control group was given traditional nursing, while the observation group was given recombinant human brain natriuretic on the basis of control group. The long or short term effect of two groups were analyzed. Results The clinical symptom and heart parameters had statistical difference between two groups（P〈0.05）.The total effective rate of observation group was higher than in the control group（72.3% vs 49.0%, P〈0.05）.The readmission and mortality of observation group was lower than in the control group（P〈0.05）. Conclusion The ecombinant human brain natriuretic peptide treatment heart failure offers significant short-term effects, and decrease rehospitalization and mortality rate.
出处
《中国继续医学教育》
2015年第18期156-157,共2页
China Continuing Medical Education
关键词
心力衰竭
重组人脑钠肽注射液
远期预后
Heart failure
Recombinant human brain natriuretic
Long-term prognosis
